Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.50 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 4/20 | 0.42 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.42 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 3/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13833580 | 0.78 | GAA (0.57) | GAACYP1A2CYP2A6LMNAALDH1A1 | |
| SCHEMBL5183094 | 0.78 | GRM2 (0.66) | GRM2POLBMAPT | |
| SCHEMBL8268239 | 0.77 | GAA (0.56) | GAACYP1A2LMNAKDM4EALDH1A1 | |
| SCHEMBL28702896 | 0.77 | GAA (0.56) | GAALMNABRD4TP53L3MBTL1 | |
| SCHEMBL30098515 | 0.77 | GAA (0.56) | GAAKDM4EALDH1A1HPGDBRD4 | |
| SCHEMBL15519326 | 0.77 | GAA (0.56) | GAALMNABRD4TP53L3MBTL1 | |
| SCHEMBL30529453 | 0.77 | GAA (0.56) | GAALMNABRD4TP53L3MBTL1 | |
| SCHEMBL8063482 | 0.77 | GAA (0.56) | GAALMNABRD4TP53L3MBTL1 | |
| SCHEMBL5140683 | 0.77 | GAA (0.56) | GAALMNABRD4TP53L3MBTL1 | |
| SCHEMBL564816 | 0.77 | GAA (0.56) | GAAKDM4EALDH1A1HPGDBRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240109900-A1 | AZABICYCLIC SHP2 INHIBITORS | PROMIDIS S.R.L. (IT) | 2024-04-04 | — | — | US | claimed |
| US-12496297-B1 | Compositions of autophagy modulating agents and uses thereof | WASHINGTON UNIVERSITY (US) | 2025-12-16 | — | — | US | disclosed |
| US-20240109900-A1 | AZABICYCLIC SHP2 INHIBITORS | PROMIDIS S.R.L. (IT) | 2024-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240109900-A1 | AZABICYCLIC SHP2 INHIBITORS | PTPN22, PTPN2, PTPN5 | GAA 1681/4885CYP1A2 4165/4885CYP2A6 2957/4885 |
| US-12496297-B1 | Compositions of autophagy modulating agents and uses thereof | BECN1, TFEB, ATG7 | GAA 168/4885CYP1A2 4578/4885CYP2A6 4384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.